Gambaran Umum
scPharmaceuticals Inc., based in the United States, operates within the biopharmaceutical sector, primarily focusing on developing innovative subcutaneous formulations of proven therapies. The company aims to transform intravenous treatments into subcutaneous administrations, thus enhancing the convenience for patients and reducing healthcare delivery costs. Key projects include scFurosemide, a subcutaneous formulation of the diuretic furosemide targeted at patients with heart failure, and other treatments that emphasize outpatient care management. By reimagining existing drugs for subcutaneous delivery, scPharmaceuticals Inc. is positioned at the forefront of facilitating home-based treatment regimes, presenting a promising potential to disrupt traditional inpatient care models significantly.
Skor Kualitas, Nilai, dan Momentum
Kartu ini menunjukkan skor Kualitas, Nilai, dan Momentum untuk perusahaan tersebut.
Laporan Laba Rugi: Pendapatan, Laba Operasional, Laba Bersih
- Nilai revenue untuk scPharmaceuticals Inc. per 2025 Jun 30 adalah 49.97 MM.
- Nilai operating income untuk scPharmaceuticals Inc. per 2025 Jun 30 adalah -66.54 MM.
- Nilai net income untuk scPharmaceuticals Inc. per 2025 Jun 30 adalah -91.72 MM.
Period End (TTM) | Revenue (MM) | Operating Income (MM) | Net Income (MM) |
2025-06-30 | 49.97 | -66.54 | -91.72 |
2025-03-31 | 41.98 | -66.68 | -90.78 |
2024-12-31 | 36.33 | -64.78 | -85.15 |
2024-09-30 | 30.28 | -63.69 | -80.11 |
2024-06-30 | 24.05 | -60.38 | -60.64 |
2024-03-31 | 17.63 | -59.70 | -57.71 |
2023-12-31 | 13.59 | -55.40 | -54.81 |
2023-09-30 | 7.50 | -49.64 | -50.25 |
2023-06-30 | 3.70 | -44.80 | -44.77 |
2023-03-31 | 2.06 | -40.47 | -40.32 |
2022-12-31 | -36.16 | -36.84 | |
2022-09-30 | -33.38 | -34.91 | |
2022-06-30 | -29.29 | -31.30 | |
2022-03-31 | -26.32 | -28.66 | |
2021-12-31 | -25.82 | -28.03 | |
2021-09-30 | -26.27 | -28.50 | |
2021-06-30 | -28.80 | -30.99 | |
2021-03-31 | -30.02 | -32.22 | |
2020-12-31 | -29.93 | -32.21 | |
2020-09-30 | -36.30 | -35.24 |
Laporan Laba Rugi: EPS
- earnings per share basic untuk scPharmaceuticals Inc. pada 2025 Jun 30 adalah -1.77.
- laba per saham yang terdilusi untuk scPharmaceuticals Inc. pada 2025 Jun 30 adalah -1.77.
Period End (TTM) | Earnings Per Share Basic | Earnings Per Share Diluted |
2025-06-30 | -1.77 | -1.77 |
2025-03-31 | -1.88 | -1.88 |
2024-12-31 | -1.91 | |
2024-09-30 | -1.96 | -1.96 |
2024-06-30 | -1.56 | -1.56 |
2024-03-31 | -1.49 | -1.49 |
2023-12-31 | -1.42 | |
2023-09-30 | -1.37 | -1.37 |
2023-06-30 | -1.32 | -1.32 |
2023-03-31 | -1.30 | -1.30 |
2022-12-31 | -1.30 | |
2022-09-30 | -1.28 | -1.27 |
2022-06-30 | -1.14 | -1.14 |
2022-03-31 | -1.05 | -1.05 |
2021-12-31 | -1.02 | |
2021-09-30 | -1.04 | -1.04 |
2021-06-30 | -1.13 | -1.14 |
2021-03-31 | -1.22 | -1.22 |
2020-12-31 | -1.31 | |
2020-09-30 | -1.57 | -1.57 |
Arus Kas: Operasi, Investasi, Pendanaan
- Nilai cash from operating activities untuk scPharmaceuticals Inc. per 2025 Jun 30 adalah -65.86 MM.
- Nilai cash from investing activities untuk scPharmaceuticals Inc. per 2025 Jun 30 adalah -0.02 MM.
- Nilai kas dari aktivitas pendanaan untuk scPharmaceuticals Inc. per 2025 Jun 30 adalah 68.19 MM.
Period End (TTM) | Cash From Operating Activities (MM) | Cash From Investing Activities (MM) | Cash From Financing Activities (MM) |
2025-06-30 | -65.86 | -0.02 | 68.19 |
2025-03-31 | -69.98 | -0.02 | 69.09 |
2024-12-31 | -70.54 | 29.30 | 70.08 |
2024-09-30 | -70.51 | 55.77 | 71.18 |
2024-06-30 | -66.54 | 32.86 | 0.83 |
2024-03-31 | -60.45 | 42.28 | 1.16 |
2023-12-31 | -59.24 | 19.96 | 14.85 |
2023-09-30 | -55.92 | -49.49 | 98.98 |
2023-06-30 | -50.67 | -15.78 | 96.44 |
2023-03-31 | -43.70 | -26.07 | 93.41 |
2022-12-31 | -34.58 | -45.86 | 77.23 |
2022-09-30 | -29.84 | 1.63 | -9.83 |
2022-06-30 | -26.81 | 0.37 | -7.35 |
2022-03-31 | -25.91 | 6.63 | -4.94 |
2021-12-31 | -27.15 | 32.13 | -2.53 |
2021-09-30 | -29.23 | 64.33 | -0.05 |
2021-06-30 | -28.87 | 25.12 | -0.13 |
2021-03-31 | -28.57 | -20.75 | 49.82 |
2020-12-31 | -27.69 | -33.46 | 60.35 |
2020-09-30 | -33.35 | -70.16 | 64.22 |
Metrik Penilaian: PE, PriceToBook, PriceToTBV
- p/e untuk scPharmaceuticals Inc. pada 2025 Jun 30 adalah -2.11.
- p/libro untuk scPharmaceuticals Inc. pada 2025 Jun 30 adalah -37.42.
- p/tbv untuk scPharmaceuticals Inc. pada 2025 Jun 30 adalah -37.42.
- P/Book
- The current closing price divided by the book value per share.
- P/TBV
- The current price divided by the tangible book value per share.
Period End (TTM) | p/e | P/Book | P/TBV |
2025-06-30 | -2.11 | -37.42 | -37.42 |
2025-03-31 | 10.48 | 10.48 | |
2024-12-31 | 5.70 | 5.70 | |
2024-09-30 | -3.80 | 24.93 | 24.93 |
2024-06-30 | -2.73 | 6.41 | 6.41 |
2024-03-31 | 4.87 | 4.87 | |
2023-12-31 | -4.47 | 4.58 | 4.58 |
2023-09-30 | -5.70 | 4.03 | 4.03 |
2023-06-30 | -9.10 | 4.84 | 4.84 |
2023-03-31 | -8.80 | 4.47 | |
2022-12-31 | 7.79 | 7.79 | |
2022-09-30 | 4.42 | 4.42 | |
2022-06-30 | -4.58 | 2.66 | 2.66 |
2022-03-31 | -5.71 | 2.84 | 2.84 |
2021-12-31 | -4.80 | 2.17 | 2.17 |
2021-09-30 | -5.85 | 2.62 | 2.62 |
2021-06-30 | |||
2021-03-31 | -3.77 | 1.61 | 1.61 |
2020-12-31 | -3.77 | 1.48 | 1.48 |
2020-09-30 | -3.44 | 1.35 | 1.35 |
Metrik Penilaian: EBitToEv, EBit3YrAvgToEv
- EBIT/EV untuk scPharmaceuticals Inc. pada 2025 Jun 30 adalah -0.49.
- EBIT (3 tahun) / EV untuk scPharmaceuticals Inc. pada 2025 Jun 30 adalah -0.35.
Period End (TTM) | EBIT/EV | EBIT (3y)/EV |
2025-06-30 | -0.49 | -0.35 |
2025-03-31 | -0.74 | -0.53 |
2024-12-31 | -0.59 | -0.42 |
2024-09-30 | -0.26 | -0.21 |
2024-06-30 | -0.42 | -0.30 |
2024-03-31 | -0.32 | -0.23 |
2023-12-31 | -0.22 | -0.17 |
2023-09-30 | -0.20 | -0.16 |
2023-06-30 | -0.12 | -0.10 |
2023-03-31 | -0.13 | -0.11 |
2022-12-31 | -0.16 | -0.15 |
2022-09-30 | -0.21 | -0.21 |
2022-06-30 | -0.30 | -0.32 |
2022-03-31 | -0.27 | -0.30 |
2021-12-31 | -0.37 | -0.41 |
2021-09-30 | -0.25 | -0.25 |
2021-06-30 | ||
2021-03-31 | -0.50 | -0.48 |
2020-12-31 | -0.47 | -0.46 |
2020-09-30 | -0.37 | -0.32 |
Efektivitas Manajemen
- roa untuk scPharmaceuticals Inc. pada 2025 Jun 30 adalah -1.39.
- roe untuk scPharmaceuticals Inc. pada 2025 Jun 30 adalah -9.81.
- roic untuk scPharmaceuticals Inc. pada 2025 Jun 30 adalah -1.92.
- croic untuk scPharmaceuticals Inc. pada 2025 Jun 30 adalah -0.02.
- ocroic untuk scPharmaceuticals Inc. pada 2025 Jun 30 adalah -1.48.
Period End (TTM) | ROA | ROE | ROIC (Tingkat Pengembalian Investasi Modal) | CROIC | OCROIC |
2025-06-30 | -1.39 | -9.81 | -1.92 | -0.02 | -1.48 |
2025-03-31 | -1.09 | -3.47 | -1.29 | 0.44 | -1.07 |
2024-12-31 | -0.85 | -2.15 | -0.96 | 0.68 | -0.85 |
2024-09-30 | -0.57 | -1.23 | -1.20 | -0.65 | -1.31 |
2024-06-30 | -0.45 | -0.76 | -0.88 | -0.26 | -0.92 |
2024-03-31 | -0.44 | -0.76 | -0.71 | -0.32 | -0.76 |
2023-12-31 | -1.04 | -1.62 | -0.56 | -0.07 | -0.63 |
2023-09-30 | -0.76 | -1.11 | -0.44 | 0.30 | -0.50 |
2023-06-30 | -0.68 | -1.00 | -0.44 | 0.30 | -0.50 |
2023-03-31 | -0.53 | -0.75 | -0.36 | 0.21 | -0.39 |
2022-12-31 | -0.40 | -0.55 | -0.79 | -0.86 | -0.68 |
2022-09-30 | -0.36 | -0.50 | -0.79 | -0.86 | -0.68 |
2022-06-30 | -0.31 | -0.42 | -0.56 | -0.60 | -0.48 |
2022-03-31 | -0.28 | -0.37 | -0.43 | -0.36 | -0.39 |
2021-12-31 | -0.26 | -0.35 | -0.37 | 0.03 | -0.35 |
2021-09-30 | -0.24 | -0.34 | -0.34 | 0.42 | -0.32 |
2021-06-30 | -0.25 | -0.32 | -0.38 | -0.05 | -0.35 |
2021-03-31 | -0.40 | -0.58 | -0.34 | 0.01 | -0.30 |
2020-12-31 | -0.42 | -0.63 | -0.31 | -0.01 | -0.27 |
2020-09-30 | -0.41 | -0.61 | -0.32 | -0.36 | -0.30 |
Gross Margins
- marjin kotor untuk scPharmaceuticals Inc. pada 2025 Jun 30 adalah 0.69.
- marjin bersih untuk scPharmaceuticals Inc. pada 2025 Jun 30 adalah -2.16.
- marjin operasi untuk scPharmaceuticals Inc. pada 2025 Jun 30 adalah -1.59.
- Margin Kotor
- The Gross Margin is the ratio of revenue left after substracting the Cost of Goods Sold. It is calculated as 1.0 - (Revenue - COGS ) / Revenue.
- Margin Keuntungan Bersih
- Margin Bersih (juga dikenal sebagai Margin Keuntungan) adalah rasio pendapatan yang tersisa setelah dikurangi Pendapatan Bersih. Perhitungannya adalah Pendapatan Bersih / Pendapatan.
- Margin Operasi
- Margin Operasi adalah rasio pendapatan yang tersisa setelah dikurangi Pendapatan Operasi. Perhitungannya adalah Pendapatan Operasi / Pendapatan.
Period End (TTM) | Margin Kotor | Margin Keuntungan Bersih | Margin Operasi |
2025-06-30 | 0.69 | -2.16 | -1.59 |
2025-03-31 | 0.69 | -2.34 | -1.78 |
2024-12-31 | 0.70 | -2.65 | -2.10 |
2024-09-30 | 0.71 | -2.52 | -2.51 |
2024-06-30 | 0.72 | -3.27 | -3.39 |
2024-03-31 | 0.72 | -4.03 | -4.08 |
2023-12-31 | 0.73 | -6.70 | -6.62 |
2023-09-30 | 0.74 | -12.10 | -12.10 |
2023-06-30 | 0.71 | -12.10 | -12.10 |
2023-03-31 | -19.54 | -19.62 | |
2022-12-31 | |||
2022-09-30 | |||
2022-06-30 | |||
2022-03-31 | |||
2021-12-31 | |||
2021-09-30 | |||
2021-06-30 | |||
2021-03-31 | |||
2020-12-31 | |||
2020-09-30 |
Pengenal dan Deskriptor
Kunci Indeks Pusat (CIK) | 1604950 |
Grupong Pang-industriya
SIC 2834 - Pharmaceutical Preparations |